Short answer
MYRIAD GENETICS INC (MYGN) filed an 8-K current report with the SEC on September 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Brian Donnelly departed as Chief Commercial Officer effective September 16, 2026.
MYRIAD GENETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Brian Donnelly departed as Chief Commercial Officer effective September 16, 2026
- Donnelly remains a non-executive employee through September 21, 2026 for transition support
- Vishal Sikri promoted from Senior Vice President, Product to Executive Vice President, Commercial
- Commercial leadership transition combines product experience with commercial responsibility
Item 7.01 · Regulation FD Disclosure
- Executive leadership transition: Donnelly departed; Sikri appointed Executive Vice President, Commercial
- Commercial leadership change may affect sales execution, go-to-market strategy, and near-term operating priorities
- Exhibit 99.1 contains the company’s press release and additional transition details
Item EX-99.1 · Exhibit EX-99.1
- Vishal Sikri promoted to Executive Vice President–Commercial, effective September 16, 2026
- Chief Commercial Officer Brian Donnelly departing Myriad on September 21, 2026
- Leadership transition places a former SVP of Product over commercial execution and growth initiatives
- Full-year 2026 financial guidance reaffirmed, limiting immediate outlook uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MYRIAD GENETICS INC 8-K filings
Get the next MYGN 8-K as it lands
Follow MYGN for push alerts, or ask the research agent what this filing means.